NMR spectroscopy metabolomic profiling of exhaled breath condensate in patients with stable and unstable cystic fibrosis

Background Metabolomics could provide new insights into the pathophysiology of cystic fibrosis (CF) by identifying profiles of endogenous metabolites. Objectives To investigate whether metabolomics of exhaled breath condensate could discriminate between patients with unstable CF, stable CF and healthy subjects, and whether selected metabolites were responsible for between-group differences. Methods Twenty-nine patients with stable CF, 24 with unstable CF and 31 healthy subjects (age 9–24 years) participated in a cross-sectional study. Metabolomics was performed with high-resolution nuclear magnetic resonance spectroscopy. Partial least squares-discriminant analysis was used as classifier. The results were validated in a second independent study. Results Intraclass correlation coefficients for between-day and technical repeatability were 0.93 and 0.96, respectively. Bland–Altman analysis showed good within-day repeatability. Correct classification rate of CF (n=53) vs healthy subjects (n=31) was 96% (R2=0.84; Q2=0.79). Model validation with a testing sample set obtained from subjects not included in the primary analysis (23 CF and 25 healthy subjects) showed a sensitivity of 91% and a specificity of 96%. The classification rate of stable CF (n=29) vs unstable CF patients (n=24) was 95% (R2=0.82; Q2=0.78). Model external validation in 14 patients with stable CF and 16 with unstable CF showed a sensitivity of 86% and a specificity of 94%. Ethanol, acetate, 2-propanol and acetone were most discriminant between patients with CF and healthy subjects, whereas acetate, ethanol, 2-propanol and methanol were the most important metabolites for discriminating between patients with stable and unstable CF. Conclusions Nuclear magnetic resonance spectroscopy of exhaled breath condensate is reproducible, discriminates patients with CF from healthy subjects and patients with unstable CF from those with stable CF, and identifies the metabolites responsible for between-group differences.

[1]  D. Geddes,et al.  Inflammation in cystic fibrosis airways: relationship to increased bacterial adherence. , 2001, The European respiratory journal.

[2]  D. Cvitkovitch,et al.  The involvement of the pyruvate dehydrogenase E1alpha subunit, in Streptococcus mutans acid tolerance. , 2008, FEMS microbiology letters.

[3]  H. Veeze,et al.  Diagnosis of cystic fibrosis. , 1995, The Netherlands journal of medicine.

[4]  A. Ghio,et al.  Mass spectrometric analysis of biomarkers and dilution markers in exhaled breath condensate reveals elevated purines in asthma and cystic fibrosis. , 2009, American journal of physiology. Lung cellular and molecular physiology.

[5]  John C. Lindon,et al.  Pattern recognition methods and applications in biomedical magnetic resonance , 2001 .

[6]  G. Corso,et al.  Metabonomic analysis of exhaled breath condensate in adults by nuclear magnetic resonance spectroscopy , 2008, European Respiratory Journal.

[7]  Viola Khodaverdi,et al.  Transcriptional regulation of the acetyl-CoA synthetase gene acsA in Pseudomonas aeruginosa , 2010, Archives of Microbiology.

[8]  G. Hanna,et al.  Repeatability of the measurement of exhaled volatile metabolites using selected ion flow tube mass spectrometry , 2010, Journal of the American Society for Mass Spectrometry.

[9]  Richard R. Ernst,et al.  Coherence transfer by isotropic mixing: Application to proton correlation spectroscopy , 1983 .

[10]  David Smith,et al.  A longitudinal study of ethanol and acetaldehyde in the exhaled breath of healthy volunteers using selected-ion flow-tube mass spectrometry. , 2006, Rapid communications in mass spectrometry : RCM.

[11]  N. Alexis,et al.  Extracellular purines are biomarkers of neutrophilic airway inflammation , 2008, European Respiratory Journal.

[12]  T. Ebbels,et al.  Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts , 2007, Nature Protocols.

[13]  J M Bland,et al.  Statistical methods for assessing agreement between two methods of clinical measurement , 1986 .

[14]  David S. Wishart,et al.  HMDB: a knowledgebase for the human metabolome , 2008, Nucleic Acids Res..

[15]  S. Wold,et al.  Orthogonal signal correction of near-infrared spectra , 1998 .

[16]  Károly Héberger,et al.  Metabolomics applied to exhaled breath condensate in childhood asthma. , 2007, American journal of respiratory and critical care medicine.

[17]  J. Emerson,et al.  Defining a pulmonary exacerbation in cystic fibrosis. , 2001, The Journal of pediatrics.

[18]  David Smith,et al.  Hydrogen cyanide as a biomarker for Pseudomonas aeruginosa in the breath of children with cystic fibrosis , 2009, Pediatric pulmonology.

[19]  T. Ferkol,et al.  Airway inflammation in cystic fibrosis. , 2008, Chest.

[20]  Tianshu Wang,et al.  The analysis of 1-propanol and 2-propanol in humid air samples using selected ion flow tube mass spectrometry. , 2006, Rapid communications in mass spectrometry : RCM.

[21]  T. M. O’Connell,et al.  Metabolomic analysis of bronchoalveolar lavage fluid from cystic fibrosis patients , 2009, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[22]  M. Phillips,et al.  Variation in volatile organic compounds in the breath of normal humans. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[23]  P. J. Barnes,et al.  Exhaled breath condensate: methodological recommendations and unresolved questions , 2005, European Respiratory Journal.

[24]  Q. Jöbsis,et al.  Biomarkers in exhaled breath condensate indicate presence and severity of cystic fibrosis in children , 2008, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[25]  Erik J. Saude,et al.  NMR analysis of neutrophil activation in sputum samples from patients with cystic fibrosis , 2004, Magnetic resonance in medicine.

[26]  P. Montuschi,et al.  Nuclear magnetic resonance-based metabolomics of exhaled breath condensate: methodological aspects , 2012, European Respiratory Journal.

[27]  R. Tirouvanziam,et al.  Primary inflammation in human cystic fibrosis small airways. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[28]  I. Berregi,et al.  Quantitative determination of caffeine, formic acid, trigonelline and 5-(hydroxymethyl)furfural in soluble coffees by 1H NMR spectrometry. , 2010, Talanta.

[29]  D. Klemp,et al.  Volatile organic compounds in the exhaled breath of young patients with cystic fibrosis , 2006, European Respiratory Journal.

[30]  David Smith,et al.  A longitudinal study of methanol in the exhaled breath of 30 healthy volunteers using selected ion flow tube mass spectrometry, SIFT-MS , 2006, Physiological measurement.

[31]  Q. Jöbsis,et al.  Structural lung changes, lung function, and non‐invasive inflammatory markers in cystic fibrosis , 2010, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[32]  S. McColley,et al.  Clinical Significance of Microbial Infection and Adaptation in Cystic Fibrosis , 2011, Clinical Microbiology Reviews.

[33]  J. Uddin,et al.  Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway , 2004, Nature Immunology.

[34]  T. Fan.  Metabolite profiling by one- and two-dimensional NMR analysis of complex mixtures , 1996 .

[35]  David Smith,et al.  Detection of volatile compounds emitted by Pseudomonas aeruginosa using selected ion flow tube mass spectrometry , 2005, Pediatric pulmonology.